Document Type
Conference Paper/Presentation
Conference
Publication Date
11-2019
Advisor(s)
John Thurmond, Ph.D.; Illinois Mathematics and Science Academy
Disciplines
Biochemistry, Biophysics, and Structural Biology | Bioinformatics | Biology | Cancer Biology | Life Sciences | Molecular Biology | Structural Biology
Abstract
The Epidermal Growth Factor Receptor (EGFR), a transmembrane protein involved in the regulation of signaling pathways, is frequently overexpressed in epithelial tumors. First generation EGFR TKIs, such as erlotinib and gefitinib, traditionally improved outcomes for non-small-cell lung carcinoma and pancreatic cancer patients by attaching competitively and reversibly to the ATP binding domain of EGFR. Second-generation EGFR TKIs have been developed to combat resistance among patients, despite demonstrating toxic side effects. In the present study, 1400 selective inhibitors were designed based on the molecular scaffolds of first and second generation EGFR TKIs. Results were refined by parameters outlined in Lipinski’s rule. Molecular simulation programs such as SeeSar, AdmetSar, SwissADME enabled the prediction of the compounds’ toxicity, binding affinity, physicochemical properties, and pharmacokinetics. For erlotinib, gefitinib, and a second-generation EGFR TKI, the binding affinity was increased by over 1,879,065 fold, 44,931 fold, and 9125 fold respectively, based on lower-boundary estimates. The data suggested that quinazoline derivatives offer the greatest inhibition of EGFR mutants, but other aromatic hydrocarbons bases may decrease cardiotoxic effects. Nitrogen substitutions and cyclic additions to the 1,2-Dimethoxyethane structures resulted in a significant increase in binding affinity to EGFR, and rigidifying linkers and adding O-H groups allowed for the decreased inhibition of the human ether-a-go-go gene. These findings may lead to further optimization of anticancer drugs and provide a computational strategy for drug design.
Related Image
Click on the image above to open a full resolution pdf
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Meng, J.
(2019).
Discovery of an EGFR Inhibitor For the Treatment of Lung and Other Cancers.
Retrieved from: https://digitalcommons.imsa.edu/student_pr/47
Poster
Discovery of EGFR kinase domain inhibitor for the treatment of lung and other cancers using first and second generation EGFR TKIs.pdf (1626 kB)
Poster
Included in
Bioinformatics Commons, Biology Commons, Cancer Biology Commons, Molecular Biology Commons, Structural Biology Commons